Gradientech welcomes investment from commercial partner

Gradientech AB (publ) ("Gradientech" or the "Company") announced on October 8 the exclusive partnership with Hardy Diagnostics for the commercialisation of its QuickMIC^® system in the United States and Canada. Alongside this partnership, Hardy Diagnostics decided to subscribe for 1,796,571 shares in Gradientech. Through the Issue, Gradientech will receive proceeds of approximately SEK 31.4 million before deduction of issue costs.

Outcome
On September 24, 2024, the Board of Directors of Gradientech AB (publ) resolved to issue a maximum of 1,796,571 shares in total, in form of a directed issue to Hardy Diagnostics. The issue provides Gradientech with approximately SEK 31.4 million before issue costs. As a result of the issue, the Company's share capital will increase by SEK 179,657.10 to a total of SEK 2,886,717.30 and the total number of shares will increase by 1,796,571 shares to 28,867,173 shares.

Advisors

Advokatfirman Lindahl KB is acting as legal advisor to Gradientech in connection with the directed issue.

For further information, please contact:

Urban Adolfsson, CFO Gradientech

Tel: +46 70 820 72 09

urban.adolfsson@gradientech.se  

About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.